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Description

The world is in the midst of a pandemic from COVID-19, a disease caused by the virus SARSCoV-2. Despite broad mitigation efforts, new cases continue with 74 million cases and 1.6
million deaths worldwide. Regardless of previous research efforts, there is no commercially
available vaccine for any coronavirus. Novel vaccine development has historically taken at
least 10 years from discovery to availability with only a 6% market entry probability.
With the global impact, there is an urgency to expedite a vaccine to protect the population.
The U.S. government launched Operation Warp Speed with the goal to produce and deliver
300 million doses of safe and effective vaccines by January 2021. Efforts toward this goal
have included coordinated government agency support, parallel clinical trial deployment,
de-risking manufacturing earlier in the development process and real-time U.S. Food &
Drug Administration evaluation of the safety and efficacy data. Safety is a priority and key
analysis has not been eliminated during the compressed timeframe. The two frontrunner
candidates show promising efficacy rates for preventing COVID-19 with Moderna reporting
94.1% efficacy and Pfizer reporting 95.0% efficacy.
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Despite the herculean efforts by scientists to develop an effective vaccine in such a short
timeframe, several national surveys suggest that public confidence in these vaccines is low
with less than 50% of the survey respondents willing to be vaccinated. According to experts,
the U.S. needs the vaccine to be at least 70–80% effective and a 70–80% vaccination rate
in order to return to normal. Significant education and promotion is planned in coordination
with the Centers for Disease Control.
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Background

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in late
2019 in Wuhan, China. The virus SARS-CoV-2
was quickly deemed to be the origin of the upper respiratory infection now called coronavirus
disease 2019 (COVID-19). Since then, the virus
has caused a global pandemic; as of December
28, 2020, there have been a reported 81 million
cases and 1.8 million deaths worldwide.1 Broad
infection mitigation efforts have been implemented including stay at home orders, mandatory masking, capacity limitations, expansion of
laboratory testing and emergency use authorization (EUA) of novel therapeutic treatments

for COVID-19. Many of these mitigation efforts
have had broad societal impacts and have
disrupted the lives of billions. Through this, the
public remains hopeful that a vaccine protecting against SARS-CoV-2 will allow a “return to
normal” and an end to the COVID-19 pandemic.
Coronavirus vaccines have been studied within
clinical trials but until recently had not been
available for widespread use. Development of
a vaccine for the 2003 SARS-CoV virus epidemic was started and eventually stalled as
the disease was tempered by traditional methods. COVID-19 shows no sign of remediation
without the development of a highly effective
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vaccine. Scientists around the world are competing in a race to produce, test and release
coronavirus vaccines to combat an already yearlong pandemic. Novel vaccines have historically
taken upwards of 10 years from discovery to
availability and have a successful development
rate of only 6%.2 To accelerate the lengthy
development and approval process (Figure 1),
the United States (U.S.) government launched
Operation Warp Speed (OWS). This initiative,
which is overseen by the Department Health
and Human Services and the Department of
Defense, has the goal to “deliver 300 million
doses of safe and effective vaccines with the
initial doses available by January 2021.”3 OWS
has coordinated government agency support,
parallel clinical trial development, preemptive
manufacturing of vaccines and real-time FDA
evaluation of safety and efficacy data. Vaccine
safety has been a priority of OWS, and key
analyses of safety data have not been eliminated nor bypassed during the compressed vaccine development timeline.3

Vaccine Approval Status

There are currently 61 COVID-19 vaccines globally that are in some stage of human clinical trials, with at least an additional 85 in preclinical
investigation.4 In the U.S., there have been two
EUA-approved vaccines, Pfizer-BioNTech and

Moderna.5,6 Two other vaccine candidates (AstraZeneca and Janssen) are currently in Phase 3
clinical trials and could submit for EUA in spring
2021. The two leading vaccines, the Pfizer
COVID-19 Vaccine and the Moderna COVID-19
Vaccine, which have both received EUA, are
based on messenger RNA (mRNA) technology. The vaccine candidates in development by
AstraZeneca and Janssen are vector-based
vaccines. Please refer to Table 1 for comparison
of the COVID-19 vaccine frontrunners.
At the time of this writing, Phase 3 data has
been announced for Pfizer, Moderna and AstraZeneca. Pfizer’s vaccine was approved for
use in the United Kingdom on December 2,
2020, received EUA in the U.S. from the FDA on
December 11, 2020 and approved by the European Medicines Agency for the European Union
on December 21, 2020.5,14,15 The Moderna vaccine
received EUA from the FDA on December 18,
2020.6 Both vaccines are currently being distributed via allocations to states.

mRNA Technology

Currently approved viral vaccines (i.e., influenza
vaccines) use either weakened viruses or viral
particles to generate an immune response,
antibody production and ultimately immunity against the targeted virus. The Pfizer and

Table 1. Comparison of COVID-19 Vaccine Frontrunners4-13
Pfizer/BioNTech
Moderna

Janssen

Name of vaccine

Pfizer-BioNTech
Moderna
COVID-19 Vaccine COVID-19 Vaccine AZD1222
BNT162b
mRNA-1273

Ad26.COV2.S

Type of vaccine

mRNA

mRNA

Vector-based

Vector-based

Route of administration IM

IM

IM

IM

Number of doses

2 doses 21 days
apart

2 doses 28 days
apart

2 doses 28
days apart

1 dose (potentially 2 doses)

Storage requirements*

-70° C

-20° C

2° to 8° C

2° to 8° C

U.S. commitments

100 million doses

200 million doses

300 million
doses

100 million
doses

Projected availability

December 15,
2020

December 21,
2020

Early/mid 2021 2021

Projected/actual
emergency use
authorization (EUA)

December 11,
2020

December 18,
2020

Early 2021

*Only long-term (up to 6 months) storage requirements shown

464

AstraZeneca

Early/Mid 2021

Figure 1. Traditional vs. Accelerated Vaccine Development Timeline for COVID-19. Adapted from
Operation Warp Speed Accelerated Process.3
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Table 2. Historical Vaccine Efficacy20-29
Disease

Efficacy*

Tetanus
Polio

100%
99-100%

Diphtheria

97%

Measles

97%

Rubella

97%

Shingles

91-97%

COVID-19

94-95%

Anthrax

93%

Chickenpox

92%

Mumps

88%

Pertussis

34-98%†

Influenza

19-60%‡

* The efficacy of non-COVID-19 vaccines reported as efficacy (determined by a
study with ideal conditions, e.g. a clinical trial) or effectiveness (determined by a
study with typical/real-world conditions) as reported by the CDC29
† Efficacy is high within the first year of vaccination but decreases by 4-5 years
‡ Based on influenza vaccines from 2010-11 to 2018-19 seasons

Moderna COVID-19 vaccines utilize a synthetic
mRNA technology. Unlike DNA, which carries
genetic information for every cell in the human
body, mRNA directs the body’s protein production. The mRNA vaccines take advantage
of this protein production process by providing
instructions to the recipient’s cells to make
a harmless spike protein that is found on the
surface of SARS-CoV-2. This spike protein is
unique to COVID-19 and part of a full protein
and will not cause harm to the patient who
is vaccinated. The resulting spike protein is
antigenic and will lead to activation of the immune system to produce antibodies and fight
off what it thinks is an infection.16 There are
currently no FDA-approved mRNA vaccines in
the U.S., but the concept has been studied for
decades. mRNA technology has the advantage
of a faster development process than traditional vaccines, as the development process
does not require growing weakened virus in lab
cultures.16 This is reflected in the current mRNA
vaccine candidates, Pfizer and Moderna, which
were the first to gather sufficient data from
Phase 3 trials to submit to the FDA for EUA
approval.
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Findings

Vaccine Trial Efficacy

The FDA and World Health Organization
(WHO) have both set minimum thresholds for
COVID-19 vaccine efficacy at 50%, with WHO
preferring at least 70% efficacy.17,18 According to
experts, a vaccine with at least 70–80% efficacy and 70–80% vaccination uptake is needed to
end the ongoing COVID-19 pandemic (reduce
the peak by >99% in a population/region) and
end the need for counter measures such as social distancing.19 COVID-19 vaccines from Pfizer
and Moderna have shown efficacy rates of
95.0% (95% confidence interval [CI] 90.0, 97.9)
and 94.1% (95% CI 89.3, 96.8), respectively.20,21
Refer to Table 2 for how these new vaccines
compare to vaccines for various other vaccine-preventable diseases. An interim analysis
for AstraZeneca’s vaccine candidate found an
efficacy of 90.0% (95% CI 67.4, 97.0) when the
vaccine was given as a half dose followed by a
full dose and 62.1% (95% CI 41.0, 75.7) when 2
full doses were given. However, given the unexpected results, additional analysis is needed to
further elucidate its efficacy.30
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Table 3. Interim Phase 3 Clinical Trial Results21,31
Pfizer-BioNTech COVID-19
Vaccine41

Moderna COVID-19 Vaccine21

Study began

July 2020

July 2020

Enrollment

>43,000 participants

>30,000 participants

Participant demographics

Age ≥65 years: 21%
Hispanic/Latinx: 28%
African: 9%
Asian: 4%

Age ≥65 years: 25%
Hispanic/Latinx: 21%
African: 10%
Asian: 5%

Efficacy rate

95.0% (95% CI 90.0, 97.9)

94.1% (95% CI 89.3, 96.8)

COVID-19 cases

Total: 170
Vaccinated group: 8
Placebo group: 162

Total: 196
Vaccinated group: 11
Placebo group: 185

Severe COVID-19 cases

Total: 10
Vaccinated group: 1
Placebo group: 9

Total: 30
Vaccinated group: 0
Placebo group: 30

COVID-19-related deaths

Total: 0
Vaccinated group: 0
Placebo group: 0

Total: 1
Vaccinated group: 0
Placebo group: 1

CI = confidence interval

Pfizer and Moderna’s COVID-19 vaccine efficacy
rates are based on data from their respective
Phase 3 trials. Details of these two trials and
the efficacy outcomes are listed in Table 3.
Both trials consisted of over 30,000 participants and included patient populations with
diverse backgrounds.20,21,31 The primary efficacy
endpoint was calculated from the proportion of
laboratory-confirmed, symptomatic COVID-19
cases in vaccinated participants versus participants who received placebo.20,21,31,32 In the
Pfizer study, laboratory-confirmed, symptomatic COVID-19 occurred in 8 participants in the
vaccinated group and in 162 participants in the
placebo group.20 In the Moderna study, the
same endpoint occurred in 11 participants in
the vaccinated group and in 185 participants in
the placebo group.21 The vaccines also showed
efficacy in preventing severe COVID-19 (e.g.,
severe illness per the National Institutes of
Health [NIH] definition, or respiratory failure, or
evidence of shock or significant acute renal, hepatic or neurologic dysfunction, or admission to
an intensive care unit [ICU], or death).20,21,31 One
participant in the vaccinated group and nine
participants in the placebo group experienced
severe COVID-19 in the Pfizer study, and zero
participants in the vaccinated group and 30
participants in the placebo group experienced
severe COVID-19 in the Moderna study. Both

Pfizer and Moderna reported that their efficacy
was consistent across age, gender, race, and
ethnicity demographics with Pfizer and Moderna reporting 94.7% (95% CI 66.7, 99.9) and
86.4% (95% CI 61.4, 95.5) efficacy, respectively,
in those age 65 years and older.21,31
While efficacy rates for the COVID-19 vaccines
from Pfizer and Moderna are high, it is important to understand the caveats of this data. Due
to the known fact that vaccines are not effective immediately, Pfizer’s study began measuring the primary efficacy endpoint 7 days after
the second dose.21,31 Moderna’s study began
measuring efficacy 14 days after the second
dose.21 As a result, recipients may not be fully
protected until at least 7 or 14 days after their
second dose for the Pfizer and Moderna vaccines, respectively. It will be important to educate recipients that infections occurring after
vaccination but prior to these time points are
due to virus exposure prior to when adequate
immunity was acquired. Furthermore, Phase
1 studies showed significantly lower immune
responses after only one dose compared to 2
doses, and Pfizer’s Phase 3 study found an efficacy rate of 52.4% (95% CI 29.5, 68.4) during
the time period after the first dose but before
the second dose. This suggests efficacy is likely
much lower after only 1 dose of vaccine.20,33,34
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Recipients should be educated on the necessity
of the second dose for adequate protection.
Timing of the 2 doses can also affect vaccine
efficacy. Generally, a vaccine with multiple doses administered too close together does not
generate an optimal immune response.35 The
Centers for Disease Control and Prevention
(CDC) recommends a “grace period” of ≤4 days
from the recommended date for the second
dose (day 21 for the Pfizer vaccine and day 28
for the Moderna vaccine). However, it is not
currently recommended that an earlier second
dose be repeated. Additionally, a delayed second dose does not warrant restarting the series, but it does increase the interval of time in
which a patient does not have full protection.36
Further research is needed to determine the
duration of COVID-19 vaccine efficacy and if
vaccination will need to be repeated or require
a booster. For example, the influenza vaccine
requires annual revaccination. The duration of
natural immunity to COVID-19 is still unknown,
but reinfection is possible. Thus, those with
prior COVID-19 infection can benefit from vaccination. Finally, it is imperative to understand
that the Pfizer and Moderna vaccines were
evaluated on their ability to prevent symptomatic COVID-19, not asymptomatic infection or
transmission. Therefore, it is currently unknown
whether the vaccines prevent asymptomatic
infection or transmission. It is recommended
that vaccinated individuals will need to continue using other preventive measures including
masking and social distancing, especially if vaccination uptake is suboptimal and cases remain
high.37,38
Efficacy continues to be evaluated even after
two COVID-19 vaccines have gained EUA. Clinical trials will continue to gather data. Additionally, the CDC intends to coordinate with other
government agencies and to leverage existing
systems (such as the Emerging Infections
Program, the COVID-2019-Associated Hospitalization Surveillance Network [COVID-NET],
and systems used to estimate influenza vaccine
effectiveness) to monitor COVID-19 vaccine
effectiveness in the general population.39

Vaccine Confidence

Vaccine confidence will play a pivotal role in the
U.S.’s ability to fight the COVID-19 pandemic.
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Research published this summer showed that
the vaccine efficacy rate would need to be at
least 70% with a vaccination rate of 75% to
prevent an epidemic and at least 80% efficacy
with 75% coverage to extinguish the ongoing
pandemic.19 Vaccination rates of at least 75%
are likely too lofty of assumptions based on recent surveys that show between 45–67% vaccination rates are expected.40,41 This research also
showed that if vaccination rates drop to 50%
and ≥5% of the population has been exposed, it
is no longer possible to extinguish an ongoing
epidemic, even when vaccine efficacy is 100%.19
This further highlights the critical need to improve COVID-19 vaccine confidence in the U.S.
Understanding the population differences in
vaccine confidence will be important to vaccine
providers and educators as well. Surveys have
found clear differences in vaccine confidence in
categories such as age, gender, political preference, education level, race/ethnicity and regions
of the country. The populations identified in
these surveys that were less likely to be vaccinated were middle age (45–64 years), females,
political status designated as Independent or
Republican, no college degree, African American and from the South and Midwest U.S.
regions. The populations that consistently have
been the most willing to receive the vaccine are
elderly (≥65 years), males, college educated,
Democrat, Asian and from the Northeast and
Western U.S. regions.40,41 (Table 4)
The most commonly reported reason for hesitancy was the speed with which these vaccines
were produced and approved, concerns about
side effects, the need for more information
on efficacy, unclear need to be vaccinated and
the cost of the vaccine.40,41 The rate of vaccine
confidence has fallen over time based on many
surveys that have taken measurements during
multiple periods. These surveys highlight the
need to address these concerns as early as
possible and through multiple communication
channels. The CDC has created a new “Vaccinate with Confidence” strategy that will be a
targeted campaign to focus on the concerns
outlined above.42 Tactics include reinforcing
trust, empowering health care providers and
engaging communities and individuals to increase collaboration.
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Table 4. COVID-19 Vaccines: Local and Systemic Adverse Reactions from Solicited Data Within 7
Days After Each Dose21,31
Pfizer-BioNTech COVID-19 Vaccine
Solicited
Dose 1
% (n/total
population)

Solicited
Dose 2
% (n/total
population)

Moderna COVID-19 Vaccine
Solicited
Dose 1
% (n/total
population)

Solicited
Dose 2
% (n/total
population)

Local Reactions
Redness

Swelling

Pain at the
Injection Site

Age 18-64 years* 4.5%
(104/2,291)

5.9%
(123/2,098)

3.0%
(344/11,406)

8.9%
(982/10,985)

Age ≥ 65 years†

7.2% (
120/1,660)

2.3%
(86/3,762)

7.5%
(275/3,692)

Age 18-64 years* 5.8%
(132/2,291)

6.3%
(132/2,098)

6.7%
(767/11,406)

12.6%
(1,389/10,985)

Age ≥ 65 years†

7.5%
(124/1,660)

4.4%
(165/3,762)

10.8%
(400/3,692)

Age 18-64 years* 83.1%
(1,904/2,291)

77.8%
(1,632/2,098)

86.9%
(9,908/11,406)

89.9%
(9,873/10,985)

Age ≥ 65 years†

66.1%
(1,098/1,660)

74.0%
(2,782/3,762)

83.2%
(3,070/3,692)

Age 18-64 years* 3.7%
(85/2,291)

15.8%
(331/2,098)

0.9%
(105/11,406)

17.4%
(1,908/10,985)

Age ≥ 65 years†

10.9%
(181/1,660)

0.3%
(10/3,762)

10.0%
(370/3,692)

Age 18-64 years* 47.4%
(1,085/2,291)

59.4%
(1,247/2,098)

38.4%
(4,384/11,406)

67.6%
(7,430/10,985)

Age ≥ 65 years†

50.5%
(839/1,660)

33.3%
(1,251/3,762)

58.3%
(2,152/3,692)

Age 18-64 years* 41.9%
(959/2,291)

51.7%
1,085/2,098)

35.3%
(4,030/11,406)

62.8%
(6,898/10,985)

Age ≥ 65 years†

25.2%
(454/1,802)

39.0%
(647/1,660)

24.5%
(921/3,762)

46.2%
(1,704/3,692)

Age 18-64 years* 21.3%
(487/2,291)

37.3%
(783/2,098)

23.7%
(2,699/11,406)

61.6%
(6,769/10,985)

Age ≥ 65 years†

28.7%
(477/1,660)

19.7%
(742/3,762)

47.1%
(1,739/3,692)

4.7%
(85/1,802)

6.5%
(118/1,802)

71.1%
(1,282/1,802)

Systemic Reactions
Fever

Fatigue

Headache

New or
Worsened
Muscle Pain

1.4%
(26/1,802)

34.1%
(615/1,802)

13.9%
(251/1,802)

Solicited: reactions were collected in an electronic diary from day 1 to day 7 after vaccination
*For Pfizer-BioNTech ages assessed were 18-55 and 8 participants were between the ages of 16 and 17 years of age
†For Pfizer-BioNTech ages assessed with ≥ 56 years of age

Speed of Approval and Production

Prior to the first EUA for the COVID-19 vaccines which occurred in under 10 months, the
fastest approval for a vaccine was the mumps
vaccine (Mumpsvax®), developed in 4 years by
Merck Pharmaceuticals in the 1960s.43 Both of
these vaccines had several years of research
done ahead of time that helped hasten their
development. The mumps vaccine utilized
research identified in the 1940s and 50s such as
the use of embryonic chicken eggs and inacti-

vated vaccine technology that use dead virus
particles.43 The COVID-19 vaccine is utilizing
information from a decade of coronavirus
research and past vaccine development efforts
for Ebola and Middle East Respiratory Syndrome (MERS). The two leading candidates for
FDA approval are also utilizing mRNA technology, which has been researched and studied for
years prior to becoming the backbone of the
COVID-19 vaccines for Pfizer and Moderna.
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Table 5. Characteristics of Populations Likely To Be Vaccinated40-41
Populations Less Likely to be Vaccinated
Populations Most Likely to be Vaccinated
•
•
•
•
•
•

Age 45–64 years
Female
Political status designated as Independent
or Republican
No college degree
African American
Living in regions of South and Midwest
U.S.

Evaluating Adverse Events

Adverse events for the Pfizer and Moderna COVID vaccines have been evaluated and
included in the published EUA Vaccine Fact
Sheets for Health care Providers.44,45 Patients
for both trials were monitored from day 1 to
day 7 after each vaccine dose, and solicited
events were documented via an electronic
diary. (Table 5) Unsolicited adverse events were
monitored for at least 28 days after each dose,
and follow-up is ongoing. Patients were evaluated for specific local and systemic adverse
events. More vaccine participants than placebo
participants reported any adverse event or a
related adverse event. In general, reactogenicity, or the inflammatory response to vaccination, was generally mild or moderate, and most
systemic reactions were less common and
milder in older adults than in younger adults.
Systemic reactogenicity was more common
and severe after the second dose than after
the first dose. Local reactogenicity was similar
after the two doses. For the Pfizer vaccine, a
total of 6 patients of the 43,448 enrolled died
during the reporting period.31 Two vaccine
recipients died (1 from arteriosclerosis, 1 from
cardiac arrest), and 4 placebo recipients died
(2 from unknown causes, 1 from hemorrhagic
stroke and 1 from myocardial infarction). The
investigators concluded these deaths were
not related to the vaccine or placebo.31 For the
Moderna vaccine, a total of 13 patients of 30,351
enrolled died during the reporting period. Six
vaccine recipients died (1 from cardiac arrest, 1
after myocardial infarction, 1 from multiorgan
failure, 1 by suicide and 2 from unknown causes 37 and 57 days after the vaccine dose).21 The
investigators concluded these deaths were not
related to the vaccine.
In regards to non-solicited adverse events,
those that are likely related to both the Mod-
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•
•
•
•
•
•

Age ≥65 years
Male
Political status designated as Democrat
College educated
Asian
Living in regions of Northeast and Western
U.S.

erna and Pfizer vaccine include lymphadenopathy. The Moderna vaccine group had 3 cases of
Bell’s palsy and Pfizer had 4 cases in the vaccine
group. The rate of reported Bell’s palsy in the
vaccine groups is consistent with the rate in
the general population, and there is no basis
to conclude a causal relationship. However, the
FDA is recommending surveillance for cases of
Bell’s palsy for the vaccines.21,31
The most common non-fatal serious adverse
events for Pfizer group were appendicitis
(0.04%), acute myocardial infarction (0.02%)
and cerebrovascular accident (0.02%).44 The
most common non-fatal serious adverse events
for the Moderna vaccine was 2 cases of facial
swelling in vaccine candidates with a history of
dermatological fillers. It has been determined
that the swelling is likely related to the vaccine.45
Severe anaphylaxis has been reported with
the Pfizer COVID-19 Vaccine since its release
for the first phase of vaccinations in the UK
and U.S.46-48 The CDC has recommended that
patients with a history of anaphylaxis due to
any cause be monitored for thirty minutes
after vaccine injection.48 Appropriate medical
treatment for severe allergic reactions must
be immediately available in the vaccine clinic in
the event that an acute anaphylactic reaction
occurs following administration of a COVID-19
vaccine.48

Special Patient Populations

Special populations often include subsets of
the population where clinical trials are difficult
to administer or where there are too few recipients in the subset to make recommendations.
CDC guidance (Table 6) has been issued on the
Pfizer COVID-19 Vaccine for special populations
and is subject to change as new information
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Table 6. Considerations for Special Patient Populations36
Special Population
CDC Recommendation
Current History of
Vaccination of persons with known current SARS-CoV-2 infection
SARS-CoV-2 Infection should be deferred until the person has recovered from the acute illness
and has met CDC criteria to discontinue isolation. Consider waiting up
to 90 days post infection.
Prior History of
Vaccination should be offered to persons regardless of history of prior
SARS-CoV-2 Infection symptomatic or asymptomatic SARS-CoV-2 infection. Consider waiting
up to 90 days post infection.
Previous Passive
Antibody Therapy for
COVID-19

Vaccination should be deferred for at least 90 days, as a precautionary
measure until additional information becomes available, and to avoid
interference of the antibody treatment.

Underlying Medical
Conditions

Vaccine may be administered to persons with underlying medical conditions who have no contraindications to vaccination.

Immunocompromised Data are not currently available to establish safety and efficacy. May still
Persons
receive COVID-19 vaccination but the person should be counseled about
the unknown safety and efficacy and potential for reduced immune
response.
Pregnant Persons

No available data on safety of COVID-19 vaccines in pregnant persons.
Experts believe that mRNA vaccines are unlikely to pose a risk for people who are pregnant. Pregnant persons may choose to be vaccinated
but should consult with their healthcare providers to weigh the risks
and benefits.

Lactating Persons

No data on the safety of COVID-19 vaccines in lactating people. mRNA
vaccines are not thought to be a risk to the breastfeeding infant. A
lactating person may choose to be vaccinated and should consult with
their healthcare provider to weigh the risks and benefits.

Adolescents
(Age 16–17)

Vaccine safety and efficacy data in this group are limited to 153 participants. No safety concerns were identified and no biologically plausible
reasons identified to differentiate them from persons 18 years of age
and older. With appropriate assent, adolescents aged 16-17 may receive
the vaccine.

becomes available. The overarching theme of
the recommendations are that the benefit of
protection against SARS-CoV-2 infection outweighs the risk of the vaccine data limitations.

Cost and Access

One of the core principles of OWS is to bring
the vaccine to market as rapidly as possible
while ensuring that any vaccine developed
using U.S. tax dollar funded programs will be
supplied free of charge to the population. HHS
has worked with the Centers for Medicare and
Medicaid Services, as well as private insurers, to ensure that patients will have access
to COVID-19 vaccines with no out-of-pocket
costs. This allows vaccine access to all U.S. citizens and removes insurance and affordability
concerns.49

Conclusion

The world is ready to return to some level
of normalcy and remedy the burden of this
pandemic on human lives, social capital and
financial resiliency. However, the commitment
of community and individual accountability
is paramount. We are all part of the solution.
COVID-19 vaccines are a critical part of the
strategy to ending the perils of this pandemic.
The efficacy and safety data for the vaccines
is slowly entering into the public sector for our
review and scrutiny. Each person will need to
weigh the risk and benefit of the vaccine with
local health care professionals for their own
health and future. Being aware of the science
and safety of the vaccines will help local health
care providers with the conversations and
recommendations for their patients. There is
471

HCA Healthcare Journal of Medicine

still much work to be done, but the race for
the vaccine has produced two EUA approved
vaccines giving hope for a solution.
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